As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period
Launched by HAT YAI MEDICAL EDUCATION CENTER · Dec 31, 2019
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
The study will measure the efficacy of as-needed low dose ICS/ LABA in well controlled asthmatic patient comparing with low dose ICS in step down circumstance.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients who have been diagnosed as asthma at least 6 months.
- • 2. Patients who have well controlled asthma by ACT \> 23 and ACQ-7 \< 0.75 at least 12 weeks with using budesonide/formoterol (160/4.5 μg/d) twice daily
- • 3. Patient who not be taking oral bronchodilator such as montelukast, theophylline, doxophylline but accept for taking anti histamine and intranasal steroid.
- • 4. Patients who able to do spirometry without contraindication.
- Exclusion Criteria:
- • 1. History of using systemic steroid previous 12 week and respiratory infection History of pulmonary tuberculosis with residual lung lesion by chest radiograph recent serious medical condition such as myocardial infarction, stroke, pneumonia etc.
- • 2. History smoking less than 10 pack-years or be smoking
- • 3. History of asthma exacabation previous 12 week
About Hat Yai Medical Education Center
Hat Yai Medical Education Center is a leading institution dedicated to advancing medical education, research, and clinical trials in southern Thailand. With a commitment to improving healthcare outcomes, the center collaborates with various healthcare professionals and organizations to conduct rigorous clinical research aimed at enhancing patient care and treatment methodologies. Its state-of-the-art facilities and interdisciplinary approach foster an environment conducive to innovation and excellence in medical research, ensuring adherence to the highest ethical and scientific standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hat Yai, Songkhla, Thailand
Patients applied
Trial Officials
Narongwit Nakwan, M.D.
Principal Investigator
HatYai Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials